Judge Invalidates Bristol-Myers Patent For Hepatitis B Drug

Law360, New York (February 12, 2013, 3:21 PM EST) -- A Delaware federal judge on Monday struck down a Bristol-Myers Squibb Co. patent on the hepatitis B drug Baraclude as obvious, a ruling in favor of generic drugmaker Teva Pharmaceutical Industries Ltd., which had challenged the patent's validity.

In a 171-page memorandum opinion, U.S. Magistrate Judge Christopher J. Burke found in favor of invalidity claims made by Teva Pharmaceuticals USA Inc., which Bristol-Myers sued for alleged infringement over plans to make generic entecavir, a hepatitis B medication that Bristol-Myers sells under the trade name Baraclude....
To view the full article, register now.